Trials / Completed
CompletedNCT02881190
Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid Tumors
A Tolerance, Safety and Pharmacokinetic Ascending Dose Phase I Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive Malignant in Advanced Malignant Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 57 (actual)
- Sponsor
- RemeGen Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A tolerance, safety and pharmacokinetic ascending dose phase I Study of RC48-ADC administered intravenously to subjects with HER2-positive malignant in advanced malignant solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RC48-ADC |
Timeline
- Start date
- 2015-12-14
- Primary completion
- 2019-06-27
- Completion
- 2019-11-08
- First posted
- 2016-08-26
- Last updated
- 2020-06-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02881190. Inclusion in this directory is not an endorsement.